MacroGenics, Inc. (MGNX): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a biopharmaceutical company navigates the complex world of cancer treatment development? MacroGenics, Inc. (MGNX) stands out as a key player, but how exactly does it operate and generate revenue? Keep reading to discover the fascinating history, ownership structure, and mission that drive this innovative company, plus a detailed look at its unique business model and financial performance, including the $150 million in total revenue for 2024.

MacroGenics, Inc. (MGNX) is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based therapeutics for the treatment of cancer. The company was founded in 2000 and is headquartered in Rockville, Maryland. MacroGenics generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The company's mission is to improve the lives of patients with cancer by developing innovative and effective therapies.

Here's a breakdown of MacroGenics:

• History: Founded in 2000.
• Mission: Discovering, developing, manufacturing, and commercializing antibody-based therapeutics for cancer treatment.
• Headquarters: Rockville, Maryland.

As of April 11, 2025, MacroGenics' stock is trading at $1.29 per share. Let's delve into who owns MacroGenics and how it operates.

Ownership

MacroGenics has a mix of institutional and insider ownership. Key institutional shareholders include Bellevue Group AG, Armistice Capital, BlackRock, Inc., and Vanguard Group Inc. As of December 31, 2024, institutional ownership stood at 88.72%.

• Institutional Ownership: 88.72%

Here are some of the top institutional investors:

• Bellevue Group AG: 9,929,963 shares
• Armistice Capital LLC: 6,276,000 shares
• BlackRock, Inc.: 4,645,383 shares
• Vanguard Group, Inc.: 4,316,681 shares

Significant insider ownership includes Scott Koenig, the President and CEO. In late October 2024, MacroGenics announced that Scott Koenig intends to step down as President and CEO early next year. As of March 2025, Koenig holds 1,372,677 shares.

How MacroGenics Works

MacroGenics specializes in developing monoclonal antibody-based therapeutics. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. These platforms allow MacroGenics to create differentiated molecules and bio-betters designed to improve upon currently marketed drugs.

Key aspects of their operations include:

• Technology Platforms: Utilizes next-generation antibody engineering platforms.
• Product Pipeline: Focuses on oncology and autoimmune diseases.
• Strategic Collaborations: Partners with global pharmaceutical and biotechnology companies.

MacroGenics' pipeline includes several product candidates in clinical development:

• Lorigerlimab: A bispecific DART molecule targeting checkpoint inhibitors PD-1 and CTLA-4.
• MGC026: An ADC targeting B7-H3.
• MGC028: An ADC targeting ADAM9.

How MacroGenics Makes Money

MacroGenics generates revenue through collaborative agreements, net sales, contract manufacturing revenues, milestone payments, licensing fees, and royalties. A significant portion of their revenue comes from strategic partnerships and licensing agreements.

In 2024, MacroGenics reported a total revenue of $150 million, a substantial increase from $58.7 million in 2023. This increase was primarily driven by milestone payments under the Incyte License Agreement. However, the company also reported a net loss of $67 million for 2024, compared to a net loss of $9.1 million in 2023, due to increased research and development expenses.

Key revenue drivers include:

• Collaborative Agreements: $118.9 million in 2024.
• Sale of MARGENZA: A $36.3 million gain recognized in 2024.

Financial highlights for 2024 include:

• Total Revenue: $150 million (up from $58.7 million in 2023)
• Net Loss: $67 million (compared to $9.1 million in 2023)
• R&D Expenses: $177.2 million (up from $166.6 million in 2023)
• Cash Balance: $201.7 million as of December 31, 2024

MacroGenics, Inc. (MGNX) History

MacroGenics, Inc. Founding Timeline

Year established

The company was established in 1993.

Original location

The company was founded in Rockville, Maryland.

Founding team members

The founding team included:

• Scott Koenig, M.D.

Initial capital/funding

The initial funding details are not available in the provided context.

MacroGenics, Inc. Evolution Milestones

MacroGenics, Inc. Transformative Moments

Several transformative moments have shaped MacroGenics' trajectory:

• Strategic Collaborations: Forming partnerships with major pharmaceutical companies like Genentech provided crucial funding and validation for MacroGenics' technology platforms.
• Technological Advancements: The development and refinement of its DART (Dual-Affinity Re-Targeting) and Fc optimization technologies have been central to creating a diverse pipeline of innovative immuno-oncology therapies.
• FDA Approval of Margenza: The approval of Margenza in 2020 was a pivotal moment, transitioning MacroGenics from a research and development company to a commercial entity.
• Focus on Immuno-Oncology: Concentrating efforts on immuno-oncology has allowed MacroGenics to capitalize on the growing understanding and importance of the immune system in cancer treatment.
• Pipeline Expansion: Expanding the pipeline to include various bispecific and multi-specific antibodies has broadened the potential therapeutic applications and market opportunities for the company.

Explore more about the company's mission, vision, and core values: Mission Statement, Vision, & Core Values of MacroGenics, Inc. (MGNX).

MacroGenics, Inc. (MGNX) Ownership Structure

Understanding the ownership structure of MacroGenics, Inc. provides key insights into its governance and strategic direction. The company's ownership is distributed among institutional investors, individual shareholders, and company insiders.

MacroGenics, Inc.'s Current Status

MacroGenics, Inc. is a public company, trading under the ticker symbol MGNX on the Nasdaq Global Select Market. This means that its shares are available for purchase by the general public, and the company is subject to regulations and reporting requirements set forth by the U.S. Securities and Exchange Commission (SEC).

MacroGenics, Inc.'s Ownership Breakdown

The ownership of MacroGenics, Inc. is distributed among various types of shareholders. Here's a breakdown:

As of the fiscal year 2024, institutional investors hold a significant majority of MacroGenics' outstanding shares, accounting for approximately 89.18%. This substantial institutional ownership indicates strong interest and investment from major financial entities. Individual investors hold approximately 10% of the company's shares. Company insiders, including officers and directors, hold a smaller percentage, around 0.82%, of the company's stock.

MacroGenics, Inc.'s Leadership

The leadership team at MacroGenics, Inc. plays a crucial role in guiding the company's strategic initiatives and overseeing its operations. Here are some of the key figures:

• Scott Koenig, M.D.: President and Chief Executive Officer
• James Karrels: Senior Vice President and Chief Financial Officer
• Jon Wigginton, M.D.: Senior Vice President and Chief Medical Officer

These individuals, along with other members of the executive team, bring a wealth of experience and expertise to MacroGenics, Inc., driving its mission to develop innovative cancer therapies. Delve deeper into MacroGenics, Inc.'s financial standing: Breaking Down MacroGenics, Inc. (MGNX) Financial Health: Key Insights for Investors

MacroGenics, Inc. (MGNX) Mission and Values

MacroGenics is dedicated to developing innovative treatments for cancer, emphasizing patient care and ethical practices.

[Company's] Core Purpose

Official mission statement

MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

• The company aims to transform the lives of patients with cancer.
• They apply expertise in protein engineering and other technical capabilities.
• Teamwork and a shared commitment to excellence are integral to their mission.

Vision statement

MacroGenics' vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to positively impact human health worldwide.

Company slogan/tagline

While MacroGenics doesn't have a single, official slogan, their core values and actions reflect a commitment to:

• Patients First: Striving to provide life-changing medicines.
• Innovation: Developing breakthrough medicines and continuously improving.
• Integrity: Honest, transparent, and ethical conduct.

These values guide the company's strategies and culture. MacroGenics' Living Values include:

• Patients First
• Do it Right
• Innovate
• Pitch In
• Take Action
• Be Inclusive

These values represent the foundation of their company culture and help define their business strategies. MacroGenics is committed to providing employees with a comprehensive and competitive benefits program. The company had revenue of $58.7 million in 2023.

For insights into the company's financial performance, you might find this resource helpful: Breaking Down MacroGenics, Inc. (MGNX) Financial Health: Key Insights for Investors

MacroGenics, Inc. (MGNX) How It Works

MacroGenics, Inc. is a biopharmaceutical company that focuses on discovering and developing innovative, antibody-based therapeutics for the treatment of cancer. They leverage their proprietary technology platforms to create product candidates designed to address significant unmet medical needs.

MacroGenics, Inc.'s Product/Service Portfolio

MacroGenics, Inc.'s Operational Framework

MacroGenics operates through a multifaceted approach encompassing research and development, clinical trials, and strategic partnerships to bring its innovative therapies to market. Key aspects of their operational framework include:

• Research and Development: MacroGenics invests heavily in R&D to discover and develop novel antibody-based therapeutics. Their proprietary DART (Dual-Affinity Re-Targeting) and TRIDENT platforms enable the creation of bispecific and multi-specific antibodies designed to enhance efficacy and safety.
• Clinical Trials: The company conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates. These trials range from Phase 1 studies to assess safety and dosage, to Phase 3 studies designed to demonstrate clinical benefit and support regulatory approval.
• Regulatory Affairs: MacroGenics works closely with regulatory agencies like the FDA to secure approval for its products. This involves submitting comprehensive data packages and complying with strict regulatory requirements.
• Manufacturing: Ensuring a reliable supply of its products is crucial. MacroGenics manages manufacturing through a combination of in-house capabilities and partnerships with contract manufacturing organizations (CMOs).
• Commercialization: Upon regulatory approval, MacroGenics commercializes its products through its own sales and marketing efforts, as well as through partnerships with other pharmaceutical companies.
• Partnerships and Collaborations: Strategic collaborations are integral to MacroGenics' business model. These partnerships can provide funding, access to new technologies, and expanded market reach. For example, they collaborate with other companies to develop and commercialize their product candidates in specific regions or indications.

MacroGenics, Inc.'s Strategic Advantages

MacroGenics has several strategic advantages that enable its success in the competitive biopharmaceutical industry:

• Proprietary Technology Platforms: Their DART and TRIDENT platforms enable the creation of novel bispecific and multi-specific antibodies with unique mechanisms of action. This technology provides a competitive edge in developing innovative cancer therapies.
• Focus on Immuno-Oncology: MacroGenics is at the forefront of immuno-oncology, developing therapies that harness the power of the immune system to fight cancer. This focus aligns with a major trend in cancer treatment and positions the company for long-term growth.
• Experienced Management Team: A skilled leadership team with a proven track record in drug development and commercialization guides the company. Their expertise is crucial for navigating the complexities of the biopharmaceutical industry.
• Strong Intellectual Property Portfolio: MacroGenics has a robust intellectual property portfolio protecting its technology and product candidates. This provides a competitive advantage and helps to maintain market exclusivity.
• Strategic Partnerships: Collaborations with leading pharmaceutical companies provide financial resources, development expertise, and commercial infrastructure. These partnerships accelerate the development and commercialization of MacroGenics' products.

To gain more insights into the financial aspects of MacroGenics, Inc., you can explore: Breaking Down MacroGenics, Inc. (MGNX) Financial Health: Key Insights for Investors

MacroGenics, Inc. (MGNX) How It Makes Money

MacroGenics, Inc. primarily generates revenue through the development and commercialization of innovative cancer therapies, focusing on antibody-based therapeutics.

MacroGenics, Inc.'s Revenue Breakdown

MacroGenics derives its revenue from several key streams, reflecting a diversified approach to funding its research and development activities.

MacroGenics, Inc.'s Business Economics

MacroGenics operates within the competitive landscape of the biotechnology industry, where innovation and strategic collaborations are vital for success. Here are key aspects of its business economics:

• Pricing Strategy: MacroGenics prices its products, such as MARGENZA, based on the value they provide to patients and healthcare systems, considering factors like efficacy, safety, and competitive alternatives.
• Collaboration Agreements: A significant portion of MacroGenics' revenue comes from collaboration agreements with other pharmaceutical companies. These agreements typically involve upfront payments, milestone payments, and royalties on future sales of co-developed products.
• Research and Development (R&D) Investment: The company invests heavily in R&D to discover and develop new cancer therapies. These investments are crucial for maintaining a pipeline of innovative products and driving long-term growth.
• Cost of Goods Sold (COGS): Includes the direct costs associated with manufacturing and distributing products like MARGENZA. Managing COGS efficiently is important for maintaining profitability as product sales increase.
• Operating Expenses: These include selling, general, and administrative (SG&A) expenses, as well as research and development expenses. Efficient management of operating expenses is essential for maximizing profitability.

To delve deeper into the company's mission, vision, and core values, explore: Mission Statement, Vision, & Core Values of MacroGenics, Inc. (MGNX).

MacroGenics, Inc.'s Financial Performance

MacroGenics' financial performance reflects its stage as a growing biotechnology company with a focus on research and development. Key aspects of its financial performance include:

• Revenue Growth: MacroGenics has experienced revenue growth driven by increased sales of MARGENZA and continued collaboration revenue.
• Gross Margin: The gross margin on product sales is an important indicator of profitability. Factors such as manufacturing costs, pricing, and sales volume influence the gross margin.
• Operating Loss: As is typical for biotechnology companies in the development stage, MacroGenics has historically reported operating losses due to significant R&D investments.
• Cash Position: Maintaining a strong cash position is crucial for funding ongoing research and development activities. MacroGenics manages its cash reserves through a combination of revenue generation, collaboration agreements, and financing activities. As of February 22, 2024, MacroGenics reported cash, cash equivalents, and marketable securities of $239.4 million.
• Net Loss: Reflects the overall profitability of the company, taking into account all revenues and expenses. The net loss is influenced by factors such as R&D spending, collaboration revenue, and product sales.

MacroGenics, Inc. (MGNX) Market Position & Future Outlook

MacroGenics is strategically positioned as a biopharmaceutical company focusing on immuno-oncology, with a pipeline of innovative antibody-based therapeutics. Their future outlook hinges on the successful development and commercialization of these novel treatments, as well as strategic partnerships to expand their market reach.

Competitive Landscape

Opportunities & Challenges

Industry Position

MacroGenics holds a unique position in the immuno-oncology space due to its proprietary DART® (Dual-Affinity Re-Targeting) platform. This technology allows the company to develop bispecific antibodies that can simultaneously target two different antigens on cells, offering potential advantages over traditional monoclonal antibodies.

• Focus on innovative antibody-based therapeutics.
• Strong intellectual property portfolio around the DART® platform.
• Strategic collaborations with leading pharmaceutical companies.

To learn more about the company's mission, vision, and core values, visit: Mission Statement, Vision, & Core Values of MacroGenics, Inc. (MGNX).